Home » Glaxo Halts Development of Resveratrol
Glaxo Halts Development of Resveratrol
GlaxoSmithKline PLC stopped development of SRT501, a drug designed to mimic the benefits of red wine, saying the medication didn’t work well enough in cancer patients and could worsen kidney damage.
boston
boston
Upcoming Events
-
07May
-
14May
-
30May